STOCK TITAN

Vistagen to Present at the Jefferies Global Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Vistagen, a late clinical-stage biopharmaceutical company focused on innovative therapies for psychiatric and neurological disorders, announced its participation in the Jefferies Global Healthcare Conference on June 5-6, 2024, in New York City.

CEO Shawn Singh will present a fireside chat on June 6 at 11:00 a.m. EST, with a webcast available on Vistagen's website. Interested investors can arrange one-on-one meetings through their Jefferies representative.

Positive
  • Participation in a high-profile event like the Jefferies Global Healthcare Conference boosts visibility for Vistagen.
  • Opportunity for direct engagement with investors could enhance investor relations.
  • Webcast availability increases accessibility to information for a broader audience.
Negative
  • No new financial data or clinical trial results were disclosed in the announcement.
  • High dependence on conference presentation for investor engagement may not yield immediate financial benefits.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that company management will present and host one-on-one meetings during the Jefferies Global Healthcare Conference taking place June 5 and 6, 2024 in New York City.

Jefferies Global Healthcare Conference

  • Shawn Singh, Chief Executive Officer, will participate in a fireside chat on Thursday, June 6 at 11:00 a.m. Eastern Time.

A webcast will be accessible through the “Events” page in the “Investors” section of the Company’s website at www.Vistagen.com. Investors interested in arranging a one-on-one meeting during the conference should contact their Jefferies representative.

About Vistagen

Vistagen (Nasdaq: VTGN) is a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders. Five of Vistagen’s clinical-stage neuroscience pipeline candidates belong to a new class of drugs known as pherines, which are investigational neuroactive nasal sprays with innovative proposed mechanisms of action that activate chemosensory neurons in the nasal passages to impact fundamental neural circuitry in the olfactory system and the brain without the need for systemic absorption or binding to receptors in the brain. Vistagen’s sixth investigational candidate is an oral prodrug with potential to modulate NMDA receptor activity. At Vistagen, we are passionate about delivering differentiated treatments that set new standards of care for people living with anxiety, depression, and other neurological disorders. Connect at www.Vistagen.com.

Investors:

Mark A. McPartland

Vistagen Therapeutics

markmcp@vistagen.com

Media:

Caren Scannell

Vistagen Therapeutics

cscannell@vistagen.com

Source: Vistagen

FAQ

When will Vistagen present at the Jefferies Global Healthcare Conference?

Vistagen will present at the Jefferies Global Healthcare Conference on June 5-6, 2024, with a specific fireside chat on June 6 at 11:00 a.m. EST.

How can investors watch Vistagen's presentation at the Jefferies Global Healthcare Conference?

Investors can watch Vistagen's presentation via a webcast accessible through the 'Events' page in the 'Investors' section of Vistagen's website.

What is Vistagen's stock symbol?

Vistagen's stock symbol is VTGN.

Vistagen Therapeutics, Inc.

NASDAQ:VTGN

VTGN Rankings

VTGN Latest News

VTGN Stock Data

87.93M
27.06M
0.26%
58.84%
3.06%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SOUTH SAN FRANCISCO